• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

AdDIT

ADOLESCENT TYPE 1 DIABETES CARDIO-RENAL INTERVENTION TRIAL

  • Home
  • Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT)
  • How we did it
  • AdDIT Cardiovascular Assessments
  • AdDIT Results
  • AdDIT Funders
  • Contact AdDIT UK
  • Co-ordinating Centres
  • AdDIT Follow Up
  • AdDIT Follow Up active sites
  • AdDIT Publications
  • Background to AdDIT
You are here: Home / Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT)

Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT)

Reasons behind AdDIT

Young people diagnosed with type 1 diabetes during childhood are at risk of long term complications including kidney, heart and circulatory disease which may reduce life expectancy by 10 – 15 years. This risk can be reduced by improving glycaemic control (HbA1c) but this can be difficult to achieve, particularly during adolescence.  Long term complications may not appear until well into adulthood but puberty seems to be a “stress point” where signs of risk can start to develop.

In adults with type 1 diabetes, who are at higher risk of developing complications, blood pressure lowering drugs, angiotensin-converting enzyme inhibitor, (ACE inhibitor) and blood fat (cholesterol) lowering drugs (Statins) are used more and more to prevent complications.

The AdDIT study was set up by research doctors in the UK, Australia and Canada to see if giving ACE inhibitors and/or Statins during adolescence would prevent or delay long-term complications in those young people, with type 1 diabetes, who appeared to be potentially at high risk.

Why we did it

The research team were looking for information to help make decisions about how best to treat young people with diabetes in the future.

It was hoped that AdDIT would provide:

  • important data on the potential renal and cardiovascular protective effects of ACE inhibitor and/or statins in high-risk adolescents and would help to answer the question whether, in addition to strategies to achieve a good glycaemic control, additional interventions for cardio-renal protection should also be recommended in adolescents with type 1 diabetes.
  • valuable information on tolerance and safety of treatment with ACE inhibitor and statins, as well as data on compliance and potential health economics benefits.

Primary Sidebar

In this Section

  • How we did it
  • AdDIT Cardiovascular Assessments
  • AdDIT Results
  • AdDIT Funders

Footer

Co-ordinating Centres

Cookie and Privacy Policy

Site Map

  • Home
  • Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT)
  • How we did it
  • AdDIT Cardiovascular Assessments
  • AdDIT Results
  • AdDIT Funders
  • Contact AdDIT UK
  • Co-ordinating Centres
  • AdDIT Follow Up
  • AdDIT Follow Up active sites
  • AdDIT Publications
  • Background to AdDIT

Copyright © 2022  AdDIT Trial · Contact Form . Hosted by CSCS

Copyright © 2022 · Milan Pro on Genesis Framework · WordPress · Log in

  • Twitter